Clinical trials: Celecoxib
Malignant Childhood Neoplasm
Low Dose Chemotherapy Versus Best Supportive Care in Progressive Pediatric Malignancies
Many of the pediatric malignancies are not curable on progression on front line or 2nd line chemotherapy. Further therapy with conventional drugs imposes many side effects and decreases the QOL.
- Trial name
- NCT01858571
- Testing
- Low dose chemotherapy
- Where
- India
- Volunteers
- 108 people
- Sponsor
- All India Institute of Medical Sciences
Opioid Related Disorders, Opiate Addiction
Evaluation of Drug Utilization Patterns for Extended Release/Long Acting Opioids and Comparator Products
A drug utilization study will be performed to describe trends in the number of prescriptions and patients for class REMS ER/LA opioids and comparator products.
- Conditions
- Opioid Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02925806
- Testing
- Non-interventional study - retrospective database review
- Volunteers
- 5,575,834 people
- Sponsor
- ER/LA Opioid REMS Program Companies (RPC)
Survival Without Progression
A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours.
To establish the anti-tumour effect of this metronomic combination regimen defined by progression-free survival (PFS) after two cycles of treatment (4 months) and 12 months of treatment, as well as response rate after any number…
- Trial name
- SFCE METRO 01 (NCT01285817)
- Testing
- celecoxib, Vinblastine, Cyclophosphamide , methotrexate ,
- Where
- France
- Volunteers
- 79 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Recurrent Respiratory Papillomatosis
Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis
This is a randomized double blind controlled study to determine if celebrex (celecoxib), a selective COX-2 inhibitor, can decrease the rate of recurrence in adult and pediatric patients with recurrent respiratory papillomatosis.
- Trial name
- NCT00571701
- Testing
- celebrex (celecoxib)
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Northwell Health
Ligament Injury
Correlation Between Acute Analgesia and Long-Term Function Following Ankle Injuries
In this 4-arm pragmatic randomized control trial, the investigators hope to decipher whether the use of non-opioid analgesics (naproxen, celecoxib, acetaminophen) in addition to standardized physiotherapy during the acute phase…
- Trial name
- CALF (NCT02667730)
- Testing
- Acetaminophen, Naproxen, Celecoxib
- Where
- Canada
- Volunteers
- 168 people
- Sponsor
- Canadian Department of National Defence
Arthritis, Juvenile Rheumatoid
Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis
This multi-center observational Registry will collect long-term safety data on patients treated with celecoxib or non-selective nonsteroidal anti-inflammatory drugs (nsNSAIDs) as used in clinical practice for the treatment of…
- Trial name
- SINCERE (NCT00688545)
- Testing
- Celecoxib, nsNSAIDs
- Where
- 27 sites in United States
- Volunteers
- 275 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Cholangiocarcinoma
Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib
Chart Review on Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer Center with a combination of irinotecan, capecitabine and celecoxib.
- Trial name
- NCT00320918
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of New Mexico
Ankylosing Spondylitis
A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis
The investigators will recruit active ankylosing spondylitis patients for injection treatment of Human Mesenchymal Stem Cells (a prospective, open-label, masculine medicine controlled(NSAIDs), clinical trial), and collect their…
- Trial name
- NCT01709656
- Testing
- MSC, "celecoxib", "Celebrex®"
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Neuroblastoma
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
This study will combine an oral drug called DFMO with celecoxib (also oral) and two IV chemotherapy medicines called cyclophosphamide and topotecan.
- Trial name
- DFMO (NCT02030964)
- Testing
- DFMO, Celecoxib, Cyclophosphamide
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 30 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Oral Cavity Cancer
A Study of High-Risk Oral Cavity Cancer
Objectives: 1. To study the effect of anti-angiogenesis therapy on reducing the recurrence of high-risk oral cavity cancer patients after curative local treatment. 2.
- Trial name
- NCT00934739
- Testing
- Thalidomide, Celebrex, Cyclophosphamide, Dexamethasone
- Volunteers
- 150 people
- Sponsor
- National Health Research Institutes, Taiwan
Tonsillectomy, Adenotonsillectomy
Celecoxib for Pediatric Adenotonsillectomy
The investigators' study will involve the administration of either placebo or celecoxib to children aged 2 to 18 years of age undergoing tonsillectomy and assessing pain relief, impact on quality of life and side effect profile.
- Conditions
- Tonsillectomy, Adenotonsillectomy, Pain, Postoperative
- Trial name
- NCT00849966
- Testing
- Celebrex suspension
- Where
- Canada
- Volunteers
- 282 people
- Sponsor
- Children's Hospital of Eastern Ontario
Cancer
Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
This study aims to determine the efficacy of daily sirolimus and celecoxib, with low dose etoposide alternating with cyclophosphamide for pediatric participants with relapsed or refractory tumors.
- Trial name
- AflacST1502 (NCT02574728)
- Testing
- Sirolimus, Celecoxib, Etoposide
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Emory University